$68.98
3.78%
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US40637H1095
Symbol
HALO

Halozyme Therapeutics, Inc. Stock price

$68.98
-5.84 7.81% 1M
+7.06 11.40% 6M
+21.17 44.28% YTD
+8.55 14.15% 1Y
+28.92 72.19% 3Y
+42.34 158.93% 5Y
+53.95 358.95% 10Y
+66.79 3,049.77% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
-2.71 3.78%

Key metrics

Basic
Market capitalization
$8.1b
Enterprise Value
$9.0b
Net debt
$960.9m
Cash
$548.2m
Shares outstanding
117.6m
Valuation (TTM | estimate)
P/E
15.4 | 11.0
P/S
6.8 | 6.0
EV/Sales
7.7 | 6.7
EV/FCF
16.7
P/B
24.3
Financial Health
Equity Ratio
17.6%
Return on Equity
122.1%
ROCE
35.6%
ROIC
-
Debt/Equity
4.5
Financials (TTM | estimate)
Revenue
$1.2b | $1.3b
EBITDA
$753.7m | $893.6m
EBIT
$682.7m | $842.9m
Net Income
$557.3m | $739.6m
Free Cash Flow
$540.7m
Growth (TTM | estimate)
Revenue
35.0% | 32.6%
EBITDA
59.3% | 43.6%
EBIT
69.8% | 52.8%
Net Income
65.2% | 66.6%
Free Cash Flow
32.4%
Margin (TTM | estimate)
Gross
84.2%
EBITDA
64.0% | 66.4%
EBIT
57.9%
Net
47.3% | 55.0%
Free Cash Flow
45.9%
More
EPS
$4.5
FCF per Share
$4.6
Short interest
14.1%
Employees
350
Rev per Employee
$2.9m
Show more

Is Halozyme Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Halozyme Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

11x Buy
69%
4x Hold
25%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

Buy
69%
Hold
25%
Sell
6%

Financial data from Halozyme Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,179 1,179
35% 35%
100%
- Direct Costs 186 186
6% 6%
16%
992 992
42% 42%
84%
- Selling and Administrative Expenses 167 167
17% 17%
14%
- Research and Development Expense 71 71
10% 10%
6%
754 754
59% 59%
64%
- Depreciation and Amortization 71 71
0% 0%
6%
EBIT (Operating Income) EBIT 683 683
70% 70%
58%
Net Profit 557 557
65% 65%
47%

In millions USD.

Don't miss a Thing! We will send you all news about Halozyme Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Halozyme Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
4 days ago
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Director Conference Call Participants Morgan Gryga - Morgan Stanley, Research Division Brendan Smith - TD Cowen, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Divi...
Positive
Reuters
5 days ago
Halozyme Therapeutics said on Wednesday it will buy privately held Elektrofi for $750 million in cash, to expand its lineup with a technology that can deliver biologic medicines in small, concentrated doses.
Neutral
PRNewsWire
5 days ago
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year ...
More Halozyme Therapeutics, Inc. News

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Head office United States
CEO Helen Torley
Employees 350
Founded 1998
Website www.halozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today